Related Experiment Video

Updated: May 15, 2026

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors
12:03

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension

Florian Herse1, Babbette LaMarca

  • 1Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrueck Center for Molecular Medicine, Berlin, Germany.

American Journal of Reproductive Immunology (New York, N.Y. : 1989)
|January 3, 2013
PubMed

Insights

Agonist autoantibodies against the angiotensin II type 1 receptor (AT1-AA) are linked to preeclampsia, a serious pregnancy complication. These autoantibodies contribute to cardiovascular risks and other pregnancy issues.

Area of Science:

  • Reproductive immunology
  • Cardiovascular research
  • Autoimmune disorders

Background:

  • Preeclampsia is a leading cause of maternal and fetal mortality, affecting 5-10% of pregnancies globally.
  • Women with preeclampsia and their children face increased long-term cardiovascular disease risk.
  • Agonistic autoantibodies against the angiotensin II type 1 receptor (AT1-AA) are implicated in preeclampsia pathogenesis.

Purpose of the Study:

  • To review current knowledge on AT1-AA.
  • To discuss the signaling pathways activated by AT1-AA.
  • To explore the impact of AT1-AA in pregnancy complications and other autoimmune disorders.

Main Methods:

  • Literature review of studies on AT1-AA.
  • Analysis of AT1-AA detection in preeclampsia models and patients.
  • Examination of AT1-AA signaling pathways (NADPH oxidase, MAPK/ERK, NF-κB).

Main Results:

  • AT1-AA induce key pathways involved in preeclampsia.
  • AT1-AA elevate markers like sFlt1 and sEng, increase oxidative stress, and enhance endothelin-1.
  • AT1-AA are found in pregnancies with abnormal perfusion and in conditions like systemic sclerosis and renal allograft rejection.

Conclusions:

  • AT1-AA play a significant role in the pathophysiology of preeclampsia.
  • Understanding AT1-AA mechanisms offers insights into pregnancy complications and autoimmune diseases.
  • AT1-AA represent a potential target for therapeutic interventions in related disorders.

More Related Videos

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells09:29

Isolation and Adoptive Transfer of High Salt Treated Antigen-presenting Dendritic Cells

Published on: March 5, 2019

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...